| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.77 | 36.1% | 152.9% |
| Total Income | 1.77 | 36.1% | 152.9% |
| Expenditure | 1.94 | 10.9% | 43.7% |
| PBT | — | ||
| Net Profit | -0.28 | 54.8% | 56.9% |
| OPM | -9.41% | 24.87pp | 83.70pp |
| NPM | -15.69% | 31.80pp | 77.09pp |
| EPS | -0.01 | 0.0% | 0.0% |
Nuo Therapeutics Announces Q2 2026 Financial Results and Business Update
17 Aug 2026 · 17 Aug, 5:31 pm
Summary
Nuo Therapeutics announced its financial results for the second quarter of 2026, reporting total revenues of approximately $1.77 million, a significant increase of over 150% year-over-year. For the first half of 2026, total revenues were approximately $3.07 million, also showing a year-over-year increase exceeding 150%. The company also noted sequential growth, with second quarter product revenues up 38% from the prior quarter. The net operating loss for Q2 2026 improved by approximately $280,000 compared to Q1 2026, indicating progress towards operational breakeven. Management highlighted positive market dynamics and the continued positive performance of their distribution agreement.
Key Highlights
- 1
Total revenues for the second quarter of 2026 were approximately $1.77 million, representing an increase of over 150% compared to the comparable 2025 period.
- 2
Total revenues for the first half of 2026 reached approximately $3.07 million, also up in excess of 150% versus the first half of 2025.
- 3
Second quarter product revenues increased by 38% sequentially compared to the first quarter of 2026.
- 4
Aurix branded product revenues saw a sequential increase of over 30% in the second quarter of 2026.
- 5
The company reported a net operating loss of approximately $167,000 for the second quarter of 2026, an improvement of approximately $280,000 compared to the first quarter of 2026.
- 6
An amended loan agreement provided interim funding of $675,000, with $325,000 remaining available under commitments totaling $2 million.
Management Comments
David Jorden
Market dynamics continue to support attractive growth opportunities for the Aurix brand and, by extension, Smith+Nephew’s private label offering. We remain two months shy of the one-year anniversary of Smith+Nephew’s market entry and the initial availability of their private label brand as another differentiated autologous therapy and are pleased to report that the arrangement continues to perform positively. We amended January’s loan agreement in May with additional capital made available via an interim funding and have the company option to increase total borrowings under the agreement on September 30, 2026. The loan remains designed to provide working capital as we invest in growth and move closer to breakeven operations.
Informational and educational content only. Not investment advice.